Single-agent, broad-spectrum fluoroquinolones for the outpatient treatment of low-risk febrile neutropenia;Terapia sencilla con fluoroquinolonas de espectro amplio para el tratamiento ambulatorio de pacientes con fiebre neutropénico de bajo riesgo

Annals of Pharmacotherapy

Volumn 45, Issue 9, 2011, Pages 1094-1102

  Cooper, Maryann R ^a   Durand, Cheryl R ^a   Beaulac, Matthew T ^b   Steinberg, Michael ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b HOSPITAL OF SAINT RAPHAEL   (United States)

Author keywords

Febrile neutropenia; Fluoroquinolones; Neoplasm; Outpatient

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIBIOTIC THERAPY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; MONOTHERAPY; OUTPATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

ADMINISTRATION, ORAL; AMBULATORY CARE; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; FEVER; FLUOROQUINOLONES; HUMANS; NEOPLASMS; NEUTROPENIA;

EID: 80052451861     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q147     Document Type: Review

References (27)

1. Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999; 86:126-34.
2. Pizzo PA. Management of fever in patients with cancer and treatment-in- duced neutropenia. N Engl J Med 1993;328:1323-32.
3. Rolston KV. The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments. Clin Infect Dis 2004;39(suppl 1): S44-8.
4. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
5. Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 1986;80:13-20.
6. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:e56-93.
7. Pizzo PA. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552.
8. Schimpff S. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971;284:1061.
9. Freifeld A, Sankaranarayanan J, Ullrich F, Sun J. Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA. Support Care Cancer 2008;16:181-91.
10. Shams WE, Evans ME. Guide to selection of fluoroquinolones in patients with lower respiratory tract infections. Drugs 2005;65:949-91.
11. Hidalgo M, Hornedo J, Lumbreras C, et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer 1999;85:213-9.
12. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-51.
13. Uys A, Rapoport BL, Anderson R. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 2004;12:555-60.
14. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999;29:490-4.
15. Morris PG, Hassan T, McNamara M, et al. Emergence of MRSA in positive blood cultures from patients with febrile neutropenia-a cause for concern. Support Care Cancer 2008;16:1085-8.
16. Cornely OA, Wicke T, Seifert H, et al. Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. Int J Hematol 2004;79:74-8.
17. Product information. Levaquin (levofloxacin). Raritan, NJ: Ortho-Mc-Neil-Janssen Pharmaceuticals, Inc., July 2009.
18. Chamilos G, Bamias A, Efstathiou E, et al. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer 2005;103:2629-35.
19. Sebban C, Dussart S, Fuhrmann C, et al. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support Care Cancer 2008;16:1017-23.
20. Rolston KV, Frisbee-Hume SE, Patel S, Manzullo EF, Benjamin RS. Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients. Support Care Cancer 2010;18:89-94.
21. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205.
22. Garcia-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001;93:31-8.
23. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341:305-11.
24. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999; 341:312-8.
25. Innes HE, Smith DB, O'Reilly SM, Clark PI, Kelly V, Marshall E. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with can- cer: a prospective randomised controlled single centre study. Br J Cancer 2003;89:43-9.
26. Niho S, Ohe Y, Goto K, et al. Randomized trial of oral versus intra- venous antibiotics in low-risk febrile neutropenic patients with lung cancer. Jpn J Clin Oncol 2004;34:69-73.
27. Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 2006;24:4129-34.